前沿生物: 前沿生物关于第四届监事会第三次会议决议的公告

Meeting Details - The third meeting of the fourth Supervisory Board of Frontier Biopharmaceuticals (Nanjing) Co., Ltd. was held on July 18, 2025, via telecommunication voting, with all three supervisors present [1] - The meeting was chaired by Mr. Jiang Zhizhong, and the notice was sent to all supervisors on July 14, 2025, via email [1] Resolution Summary - The Supervisory Board approved the proposal to temporarily use up to RMB 200 million (including RMB 200 million) of idle funds raised from the initial public offering to supplement working capital, with a usage period not exceeding 12 months from the date of board approval [1] - The company will ensure that the use of these funds does not affect the progress of the investment projects funded by the raised capital and will return the funds to the dedicated account if the usage progresses faster [1] - The funds will only be used for business expansion and daily operations related to the main business and will not be used for stock issuance, trading, or any activities that change the intended use of the raised funds [1][2] Voting Results - The voting results for the proposal were 3 votes in favor, 0 votes against, and 0 abstentions [2]